two
protein
molecul
asymmetr
unit
two
molecul
form
typic
homodim
fig
observ
crystal
structur
cov
previou
studi
demonstr
exist
mpro
homodim
solut
also
activ
form
support
physiolog
relev
structur
find
structur
comparison
protom
complex
apo
enzym
pdb
id
c
p
chuck
k
b
wong
unpublish
work
reveal
overal
architectur
three
domain
fig
protom
common
featur
among
cov
mpro
structur
domain
residu
domain
ii
residu
togeth
form
chymotrypsinlik
fold
substratebind
site
locat
cleft
form
domain
domain
ii
catalyt
dyad
compos
lie
center
substratebind
site
domain
iii
residu
mpro
compos
globular
antiparallel
cluster
uniqu
featur
cov
mpro
requir
homodim
format
domain
iii
connect
domain
ii
long
loop
region
residu
xray
dataprocess
refin
statist
includ
tabl
michael
acceptor
inhibitor
fig
undergo
mechanismbas
inhibit
achiev
coval
irrevers
inactiv
shown
equat
inhibitor
first
form
revers
complex
ei
enzym
equilibriumbind
constant
ki
undergo
nucleophil
attack
activ
site
cy
enzym
lead
format
stabl
coval
bond
ei
step
govern
inactiv
rate
constant
use
cov
consensu
substrat
report
first
determin
valu
km
kcat
apo
enzym
mpro
respect
tabl
cross
comparison
mpro
human
cov
reveal
kinet
paramet
mpro
rel
close
sarscov
km
kcat
rather
km
higher
kcat
approxim
ten
fold
larger
ad
inhibitor
kinet
assay
mpro
calcul
ki
respect
tabl
although
ki
higher
compar
sarscov
indic
lower
affin
inhibitor
apo
enzym
significantli
larger
strongli
support
abil
achiev
mechanismbas
irrevers
inhibit
mpro
analysi
complex
structur
mpro
bound
inhibitor
provid
insight
inhibit
mechan
fig
sinc
bind
protom
b
similarli
look
bind
mode
protom
vinyl
group
inhibitor
form
standard
coval
bond
atom
evidenc
clear
electron
densiti
fig
indic
michael
addit
reaction
occur
catalyt
site
compar
apo
enzym
one
specif
conform
observ
due
format
coval
bond
exist
doubl
conform
apo
enzym
carbonyl
oxygen
ester
close
backbon
nh
backbon
nh
fig
mimic
tetrahedr
oxyanion
intermedi
state
form
serin
proteas
cleavag
provid
addit
support
anchor
michael
acceptor
benzyl
ester
part
extend
pocket
form
van
der
waal
interact
fig
comparison
molecular
surfac
mpro
complex
apo
enzym
reveal
pocket
accommod
undergo
signific
conform
chang
upon
inhibitor
bind
fig
b
follow
imidazol
group
swift
toward
hydrophob
core
protein
better
accommod
site
main
chain
residu
constitut
outer
wall
subsit
move
toward
lactam
ring
caus
shrink
pocket
residu
flip
act
lid
cover
subsit
residu
extend
opposit
direct
host
follow
section
describ
detail
structur
featur
subpocket
coronavir
mpro
known
strong
prefer
glutamin
q
site
substrat
genom
sequenc
analysi
reveal
mpro
cleavag
site
bear
glutamin
posit
except
recognit
site
helicas
exonucleas
histidin
replac
glutamin
featur
uniqu
genom
contrast
glutamin
exclus
residu
among
cleavag
site
four
human
cov
includ
sarscov
merscov
novel
substrat
specif
impli
uniqu
structur
featur
subpocket
crystal
structur
mpro
show
size
pocket
compar
smaller
sarscov
clearli
smaller
pocket
could
better
accommod
smaller
side
chain
histidin
residu
facilit
cleavag
weaken
oxyanion
hole
form
enzymeinhibitor
complex
structur
lactam
ring
molecul
serv
structur
analog
glutamin
histidin
posit
fig
protrud
pocket
form
hydrogen
bond
lactam
oxygen
imidazol
ring
nh
fig
c
similar
complex
structur
sarscov
mpro
mpro
inhibitor
furthermor
nh
lactam
ring
form
two
hydrogen
bond
carbonyl
oxygen
atom
respect
provid
addit
support
stabil
lactam
ring
pocket
backbon
nh
residu
also
form
hydrogen
bond
backbon
carbonyl
oxygen
favor
accommod
pocket
posit
natur
mpro
cleavag
site
across
genom
six
human
cov
usual
prefer
hydrophob
residu
tabl
surpris
residu
complet
ident
among
cleavag
site
two
alphacoronavirus
major
case
leucin
residu
occupi
posit
valin
isoleucin
hand
variat
observ
posit
among
betacoronavirus
altern
residu
methionin
phenylalanin
prolin
might
indic
less
stringenc
specif
site
inhibitor
mimic
side
chain
leucin
order
cover
maximum
spectrum
natur
mpro
substrat
human
observ
structur
aliphat
isobutyl
side
chain
protrud
deep
pocket
via
interact
alkyl
portion
side
chain
well
accommod
onto
van
der
waal
surfac
pocket
fig
determin
structur
divers
pocket
superimpos
backbon
four
know
mpro
structur
human
cov
lid
pocket
cover
tight
loop
residu
fig
interestingli
region
sarscov
adopt
secondari
structur
helix
maintain
differ
might
partial
account
increas
variat
natur
residu
observ
genom
betacoronavirus
side
chain
inhibitor
solvent
expos
two
protom
mpro
fig
consist
fact
specif
particular
side
chain
exist
posit
cleavag
site
among
cov
nh
carbonyl
oxygen
backbon
form
two
hydrogen
bond
backbon
carbonyl
oxygen
nh
respect
help
anchor
inhibitor
mpro
locat
posit
inhibitor
alanin
side
chain
readili
insert
rel
shallow
pocket
fig
form
hydrophob
interact
also
backbon
nh
alanin
residu
donat
hydrogen
bond
carbonyl
oxygen
fig
isoxazol
make
van
der
waal
interact
backbon
residu
fig
overal
pattern
interact
mpro
posit
similar
sarscov
mpro
far
whole
genom
sequenc
mani
strain
deposit
ncbi
strain
isol
patient
specimen
date
back
past
three
decad
sever
countri
includ
netherland
unit
state
china
high
percentag
sequenc
variat
among
clinic
isol
strain
evid
vivo
recombin
coinfect
cov
document
especi
ntermin
domain
spike
protein
order
determin
efficaci
inhibitor
sequenc
variat
accumul
circul
human
popul
assess
level
sequenc
structur
conserv
molecular
target
inhibitor
among
differ
clinic
isol
sequenc
mpro
retriev
strain
avail
genom
sequenc
supplementari
tabl
align
perform
determin
sequenc
variat
among
clinic
isol
mpro
sequenc
strain
amsterdam
use
overal
mpro
extrem
conserv
among
clinic
strain
isol
worldwid
supplementari
fig
evidenc
enzym
essenti
role
viral
replic
sequenc
variat
observ
residu
mutat
tyr
strain
isol
unit
state
mutat
arg
among
strain
cultur
vitro
mutat
ile
one
strain
isol
unit
state
fig
plot
onto
structur
mpro
residu
locat
flexibl
region
loop
molecular
surfac
fig
none
residu
directli
interact
inhibitor
provid
clear
structur
evid
support
effect
clinic
strain
spite
signific
genom
sequenc
variat
potenti
recombin
viral
transmiss
substratebind
site
mpro
shown
conserv
drug
target
design
wide
spectrum
anticov
given
evid
repetit
global
epidem
sar
mer
caus
zoonot
imper
examin
whether
substratebind
site
inhibit
mechan
employ
inhibitor
conserv
known
human
cov
relat
zoonot
cov
chose
three
repres
pair
human
cov
zoonot
counterpart
bovin
coronaviru
bcov
sarscov
sarsrel
cov
isol
bat
btsarsrcov
merscov
dromedari
camel
merscov
dcmerscov
retriev
mpro
sequenc
ncbi
databas
direct
bat
ancestor
therefor
use
mpro
sequenc
secondari
structur
present
studi
refer
sequenc
align
shown
fig
demonstr
signific
homolog
primari
amino
acid
sequenc
among
cov
closer
examin
substratebind
pocket
reveal
conserv
architectur
drug
target
fig
residu
critic
pocket
format
pocket
pocket
pocket
pocket
strictli
conserv
among
variou
cov
fig
b
peptidomimet
inhibitor
michael
acceptor
welldesign
side
chain
snugli
fit
conserv
substratebind
pocket
bind
establish
concert
interact
network
includ
coval
bond
vinyl
group
inhibitor
atom
hydrogen
bond
extens
hydrophob
interact
residu
critic
interplay
find
demonstr
inhibitor
could
exert
inhibitori
effect
toward
conserv
site
cov
zoonot
transmiss
therefor
addit
role
inhibit
known
circul
human
cov
speci
inhibitor
might
also
serv
lead
compound
preclin
clinic
test
potenti
futur
epidem
caus
cov
emerg
zoonot
origin
world
experienc
two
global
outbreak
cov
infect
sinc
enter
sarscov
merscov
caus
sever
respiratori
syndrom
high
mortal
addit
four
human
cov
name
identifi
patholog
agent
common
lack
effect
therapeut
prevent
strategi
human
cov
call
immedi
action
scientif
previous
demonstr
design
wide
spectrum
inhibitor
conserv
target
viabl
method
develop
anticov
therapeut
given
high
mutat
recombin
rate
observ
viral
abil
cov
cross
animalhuman
boundari
provid
support
strategi
inde
sever
human
cov
includ
sarscov
merscov
link
zoonot
cov
natur
infect
host
bat
dromedari
current
studi
use
mpro
model
molecul
present
crystal
structur
complex
inhibitor
base
structur
detail
resolut
substratebind
pocket
mpro
conserv
among
three
pair
human
zoonot
cov
fig
sever
key
residu
subsit
substrat
bind
complet
ident
among
seven
coronavirus
exampl
find
consist
role
mpro
viral
replic
essenti
proteolyt
process
matur
replicas
polyprotein
encod
analysi
substrat
recognit
sequenc
base
avail
whole
genom
sequenc
six
human
cov
provid
addit
evid
conserv
mpro
substratebind
pocket
posit
requir
almost
exclus
glutamin
posit
exhibit
strong
prefer
hydrophob
residu
leu
val
tabl
taken
togeth
design
wide
spectrum
inhibitor
conserv
site
mpro
studi
outlin
novel
therapeut
approach
contain
diseas
caus
exist
possibl
futur
emerg
human
cov
close
examin
interact
mpro
inhibitor
reveal
structur
detail
inhibit
mechan
synthet
peptidomimet
compound
michael
acceptor
fig
achiev
mechanismbas
enzym
inactiv
form
irrevers
coval
bond
catalyt
dyad
fig
c
success
two
serin
proteas
inhibitor
telaprevir
boceprevir
treatment
hepat
c
viru
hcv
underscor
import
coval
inhibitor
target
viral
telaprevir
boceprevir
peptidomimet
inhibitor
carri
warhead
form
coval
yet
revers
bond
catalyt
triad
serin
residu
hcv
michael
acceptor
also
use
warhead
pharmaceut
target
viral
proteas
exampl
rupintrivir
develop
inhibitor
proteas
human
rhinoviru
backbon
form
hydrogen
bond
residu
substratebind
pocket
fig
pocket
accommod
undergo
gateregul
switch
facilit
bind
inhibitor
fig
interest
phenomena
initi
observ
case
mpro
addit
structur
mpro
exhibit
sever
uniqu
interest
featur
examin
natur
cleavag
site
base
genom
sequenc
reveal
unusu
histidin
residu
uniqu
among
human
anomali
partial
accommod
rel
smaller
pocket
size
pocket
compar
smaller
sarscov
posit
seem
present
genu
specif
among
alphacoronavirus
residu
among
natur
cleavag
site
complet
ident
strong
domin
leucin
larg
variat
residu
observ
genom
human
betacoronavirus
summari
crystal
structur
mpro
complex
inhibitor
provid
critic
insight
design
irrevers
inhibitor
carri
michael
acceptor
warhead
detail
sequenc
structur
comparison
compound
demonstr
feasibl
potenti
broad
spectrum
therapeut
agent
exist
possibl
emerg
human
cov
pharmaceut
develop
coval
peptidomimet
inhibitor
would
yield
success
clinic
manag
human
coronaviru
diseas
public
health
prepared
possibl
futur
pandem
protein
express
purif
main
proteas
describ
code
sequenc
subclon
vector
transform
e
coli
cell
cell
cultur
first
grown
lb
medium
contain
ampicillin
optic
densiti
reach
protein
express
induc
ad
isopropyl
final
concentr
mm
cultur
hour
cell
pellet
harvest
centrifug
resuspend
phosphatebuff
salin
solut
supplement
mm
dithiothreitol
dtt
glycerol
cell
lysat
prepar
use
sonic
centrifug
g
min
gsttag
mpro
fusion
protein
bound
glutathion
sepharos
affin
resin
gst
tag
remov
oncolumn
cleavag
use
commerci
presciss
proteas
ge
healthcar
hour
recombin
mpro
protein
subject
addit
step
anionexchang
chromatographi
use
hitrap
q
column
ge
healthcar
elut
linear
gradient
mm
nacl
mm
trishcl
ph
glycerol
mm
dtt
purifi
protein
supplement
dmso
concentr
mg
crystal
mpro
complex
inhibitor
produc
cocrystal
inhibitor
ad
hcov
mpro
protein
molar
ratio
incub
hour
complex
centrifug
g
min
concentr
mg
buffer
contain
mm
hepe
ph
mm
nacl
mm
dtt
use
hangingdrop
vapor
diffus
method
best
crystal
obtain
day
use
reservoir
solut
contain
hepe
ph
wv
polyethylen
glycol
vv
ethylen
glycol
pdb
entri
sodium
citrat
tribas
dehydr
ph
ammonium
phosphat
monobas
ratio
data
complex
collect
resolut
k
beamlin
beij
synchrotron
radiat
facil
bsrf
use
chargecoupl
devic
detector
cryoprotect
solut
contain
vv
glycerol
wv
polyethylen
glycol
vv
ethylen
glycol
hepe
ph
data
integr
scale
perform
use
matthew
coeffici
crystal
suggest
two
molecul
per
asymmetr
unit
solvent
content
structur
complex
determin
use
molecular
replac
apoform
mpro
pdb
id
c
p
chuck
k
b
wong
unpublish
work
crossrot
translat
search
molecular
replac
perform
cycl
manual
adjust
use
subsequ
refin
use
led
final
model
crystallograph
r
factor
rcryst
free
r
factor
rfree
resolut
enzymat
assay
perform
use
fluorogen
substrat
consensu
sequenc
cov
mpro
mcaavlqsgfrli
dnp
puriti
gl
biochem
shanghai
ltd
shanghai
china
previous
fluoresc
intens
monitor
use
fluoroskan
ascent
instrument
thermo
scientif
usa
excit
emiss
wavelength
nm
nm
respect
assay
perform
buffer
solut
consist
mm
trishcl
ph
mm
edta
kinet
paramet
includ
km
kcat
apo
mpro
ki
inhibitor
determin
use
method
describ
detail
previou
cite
articl
wang
f
et
al
structur
main
proteas
human
coronaviru
insight
wide
spectrum
anticoronaviru
drug
design
sci
rep
doi
